2.1
Ruxolitinib cream (Opzelura, Incyte) is indicated for 'the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age'.
2 Information about ruxolitinib cream
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for ruxolitinib cream.
Price
2.3
The list price of ruxolitinib cream is £657.00 for a 100 g tube (Incyte website, accessed January 2026).
2.4
The company has a commercial arrangement. This makes ruxolitinib cream available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, Incyte did not disclose its Carbon Reduction Plan for UK carbon emissions.